DPP4

(redirected from DPPIV)
Also found in: Acronyms.

DPP4

A gene on chromosome 2q24.3 that encodes dipeptidyl-peptidase 4, a ubiquitous, membrane-bound enzyme with roles in nutrition, metabolism, the endocrine system, immune regulation (for instance, it is essential for T-cell receptor (TCR)-mediated T-cell activation), bone marrow mobilisation, apoptosis, cell adhesion and tumourigenesis.
References in periodicals archive ?
Dordevic et al., "Serum DPPIV activity and CD26 expression on lymphocytes in patients with benign or malignant breast tumors," Immunobiology, vol.
Protease name Cell lysates Cell medium Presenilin xxxx Neprilysin (CD10) xxx Cathepsin C xxx x Cathepsin S xxx x Cathepsin V xx Cathepsin X/Z/P xx uPA xx x DPPIV (CD26) xx Proteases are the main enzymes implicated in ECM organization and remodeling.
The algorithm does not, at this stage, suggest a role for the newer agents such as the incretins and DPPIV inhibitors.
Both incretins have a short half-life as they are rapidly degraded by dipeptidyl peptidase 4 (DPPIV).
The search for a treatment for T2DM using GLP-1 has centered on finding a GLP-1 mimetic resistant to degradation by DPPIV or designing a drug that could inhibit DPPIV, thereby prolonging the incretin effect.
It is resistant to degradation by DPPIV, and requires subcutaneous injection twice daily.
Liraglutide (long-acting GLP-1 agonist resistant to degradation by DPPIV) has a longer half-life than exenatide and can therefore be given once daily subcutaneously.
He also discussed the advantages and disadvantages of DPPIV Inhibitor groups.
Nishimura et al., "Sulphostin, a novel inhibitor of dipeptidyl peptidases IV (DPPIV) that stimulates hematopoiesis in mice," Journal of Antibiotics, vol.
There were many papers in favour of DPPIV inhibitors which it was stated offer many advantages like no weight gain but of course they are expensive, not many can afford them and they should be used with caution.